MEDICAL NEWS
Medical News
医药资讯
Updates on Japanese weight-loss medications, GLP-1 therapies, new drug development, and global pharmaceutical trends for users preparing for consultation.
Recommended Reading Order
Start with available medications in Japan, then continue with new drug development and market trends.
Medical News Articles
These articles are for educational reading and pre-consultation reference only. They do not replace diagnosis, prescriptions, or individualized medical advice.
Which GLP-1 and Weight Loss Medications Are Available in Japan?
A practical overview of GLP-1 and obesity medications used in Japan, including Semaglutide, Tirzepatide, and local treatment context.
Read articleRetatrutide Update: How Close Is It to Approval?
A clear summary of Retatrutide, its triple-agonist mechanism, clinical progress, approval status, and safety considerations.
Read articleExploring Eli Lilly’s Future Obesity Drug Pipeline
A pipeline overview covering Tirzepatide, Retatrutide, Orforglipron, and future obesity therapy directions.
Read articleNovo Nordisk vs Eli Lilly: Who Will Lead the Future of Obesity Treatment?
A comparison of the two leading companies shaping the next decade of obesity and metabolic treatment.
Read articleRetatrutide vs Tirzepatide vs Semaglutide: What Is the Difference?
Compare GLP-1, GIP, and glucagon receptor mechanisms, and understand why next-generation obesity drugs are being closely watched.
Read articleReading Note
Medical news content may change as Japanese regulations, clinical trials, and global market conditions evolve. Suitability, dosage, and risk decisions should always be confirmed by qualified medical professionals and local regulations.